Considering the relatively sustainable efficacy for MPE control for those treated with systematic chemotherapy and unsatisfactory regression in EGFR mutations, it is important to explore the radical cycles of chemotherapy for MPE NSCLC patients with EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.